Open Access Open Access  Restricted Access Subscription or Fee Access

An overview on the diagnosis and approaches in pharmacological management of Parkinson’s disease

Asad Jamal Ansari, Mohammad Khushtar, Nishat Fatima, Mohammad Monawwar, Alhamd Tanveer, Md Furquan Khan


Parkinson’s disease (PD) might be a mutual neurodegenerative disease considered by a movement disorder containing rest tremor, bradykinesia, rigidity, and postural instability, and second-leading reason of dementia and is categorized by an advanced loss of dopaminergic neurons within the neural structure alongside the occurrence of intraneuronal α-synuclein-positive enclosures. PD is identified where bradykinesia happens along with rigidity or tremor within the existence of supporting features. The diagnosis is clinical, and a spotlight should be paid to omission criteria on behalf of an auxiliary diagnosis and to ‘red flag’ structures. There is no cure or disease amending treatment for PD, and hence the rate of advance is variable. The foremost operative symptomatic treatment relics levodopa, which has greater benefits for quality of life in early PD associated with other therapies.


Amantadine, levodopa therapy, Parkinson’s disease, pergolide, ropinirole

Full Text:



Jankovic Joseph. Parkinson’s disease: clinical features and diagnosis. Journal of Neurology, Neurosurgery & Psychiatry. 2008; 79(4): 368–376.

Obeso JA et al. Past, present, and future of Parkinson’s disease: a special essay on the 200th anniversary of the shaking palsy. Movement Disorders. 2017; 32(9): 1264–1310.

Armstrong Melissa J, Michael S Okun. Diagnosis and treatment of Parkinson’s disease: a review. JAMA. 2020; 323(6): 548–560.

Dorsey E Ray, Bastiaan R Bloem. The Parkinson pandemic—a call to action. JAMA Neurology. 2018; 75(1): 9–10.

Alexander, Garrett E. "Biology of Parkinson's disease: pathogenesis and pathophysiology of a multisystem neurodegenerative disorder. Dialogues in Clinical Neuroscience 2004; 6(3): 259–280.

Haddad Fatma et al. Dopamine and levodopa prodrugs for the treatment of Parkinson’s disease. Molecules. 2018; 23(1): 40.

Asanuma Masato, Ikuko Miyazaki, Norio Ogawa. Dopamine-or L-DOPA-induced neurotoxicity: the role of dopamine quinone formation and tyrosinase in a model of Parkinson’s disease. Neurotoxicity Research. 2003; 5(3): 165–176.

Stoker Thomas B, Kelli M Torsney, Roger A Barker. Emerging treatment approaches for Parkinson’s disease. Frontiers in Neuroscience. 2018; 12: 693–703.

Braak, Heiko, et al. Staging of brain pathology related to sporadic Parkinson’s disease. Neurobiology of Aging. 2003; 24(2): 197–211.

Pasquini Jacopo et al. Progression of tremor in early stages of Parkinson’s disease: a clinical and neuroimaging study. Brain. 2018; 141(3): 811–821.

Factor SA, WM McDonald, FC Goldstein. The role of neurotransmitters in the development of Parkinson’s disease‐related psychosis. European Journal of Neurology. 2017; 24(10): 1244–1254.

Schapira, Anthony HV, K Ray Chaudhuri, Peter Jenner. Non-motor features of Parkinson’s disease. Nature Reviews Neuroscience. 2017; 18(7): 435–450.

Maillet Audrey, et al. The prominent role of serotonergic degeneration in apathy, anxiety and depression in de novo Parkinson’s disease. Brain. 2016; 139(Pt 9): 2486–2502.

Morris Rosie et al. Overview of the cholinergic contribution to gait, balance and falls in Parkinson’s disease. Parkinsonism & related disorders. 2019; 63: 20–30. 15. Chaudhuri K Ray, et al. The non-declaration of non-motor symptoms of Parkinson’s disease to health care professionals: an international study using the non-motor symptoms questionnaire. Movement Disorders. 2010; 25(6): 704–709.

Berg Daniela et al. MDS research criteria for prodromal Parkinson’s disease. Movement Disorders. 2015; 30(12): 1600–1611.

National Institute for Health and Care Excellence. Parkinson’s disease in adults; NICE guideline [NG71]. (July, 2017) [Online] Available at: adults#:~:text=This%20guideline%20covers%20diagnosing%20and,people%20aged%2018%20and%20over.&text=It%20aims%20to%20improve%20care,and%20support%2C%20and%20palliative%20care.

Massey Luke A, et al. Conventional magnetic resonance imaging in confirmed progressive supranuclear palsy and multiple system atrophy. Movement Disorders. 2012; 27(14): 1754–1762.

MacMahon DG, Sue Thomas. Practical approach to quality of life in Parkinson’s disease: the nurse’s role. Journal of Neurology. 1998; 245(Supp 1): S19–S22.

Hely Mariese A, et al. The Sydney multicenter study of Parkinson's disease: the inevitability of dementia at 20 years. Movement Disorders. 2008; 23(6): 837–844. 21. Feustel Aden C, et al. Risks and benefits of unapproved disease-modifying treatments for neurodegenerative disease. Neurology. 2020; 94(1): e1–e14.

Koller William C, Rajesh Pahwa. Treating motor fluctuations with controlled-release levodopa preparations. Neurology. 1944; 44(7 Suppl 6): S23–S28.

MacMahon DG et al. A comparison of the effects of controlled-release levodopa (Madopar CR) with conventional levodopa in late Parkinson’s disease. Journal of Neurology, Neurosurgery & Psychiatry. 1990; 53(3): 220–223.

Pahwa Rajesh et al. Comparison of standard carbidopa–levodopa and sustained‐release carbidopa–levodopa in Parkinson’s disease: Pharmacokinetic and quality‐of‐life measures. Movement disorders: Official Journal of the Movement Disorder Society. 1997; 12(5): 677–681.

Lang Anthony E, Andres M Lozano. Parkinson’s disease. New England Journal of Medicine. 1998; 339: 1130–1143.

Lesser Ronald P et al. Analysis of the clinical problems in parkinsonism and the complications of long‐term levodopa therapy. Neurology. 1979; 29(9 Pt 1): 1253–1260.

Oertel WH, Quinn NP. Parkinsonism. In Brandt T, Caplan LR, Dichgans J, Diener HC, Kennard C (eds). Neurological disorders: course and treatment. San Diego: Academic Press; 1996. pp. 715–772.

Parkinson Study Group. Effect of deprenyl on the progression of disability in early Parkinson’s disease. New England Journal of Medicine. 1989; 321(20): 1364–1371. 29. Parkinson Study Group. Mortality in DATATOP: a multicenter trial in early Parkinson’s disease. Annals of Neurology. 1998; 43(3): 318–325.

Churchyard A, et al. Autonomic effects of selegiline: possible cardiovascular toxicity in Parkinson’s disease. Journal of Neurology, Neurosurgery & Psychiatry. 1997; 63(2): 228–234.

Chase TN, TM Engber, M Maral Mouradian. Contribution of dopaminergic and glutamatergic mechanisms to the pathogenesis of motor response complications in Parkinson’s disease. Advances in Neurology. 1996; 69: 497–501.

Goetz Christopher G, et al. Chronic agonist therapy for Parkinson’s disease: A 5‐year study of bromocriptine and pergolide. Neurology. 1985; 35(5): 749–751.

Mizuno Yoshikuni, Tomoyoshi Kondo, Hirotaro Narabayashi. Pergolide in the treatment of Parkinson’s disease. Neurology. 1995; 45(3 Suppl 3): S13–S21.

Mena María Angeles, et al. Neurotoxicity of levodopa on catecholamine‐rich neurons. Movement Disorders: Official Journal of the Movement Disorder Society. 1992; 7(1): 23–31.

Yoshikawa Toshikazu, et al. Antioxidant properties of bromocriptine, a dopamine agonist. Journal of Neurochemistry. 1994; 62(3): 1034–1038.

Uitti Ryan J, J Eric Ahlskog. Comparative review of dopamine receptor agonists in Parkinson’s disease. CNS Drugs. 1996; 5(5): 369–388.

Nohria V, A Partiot. A review of the efficacy of the dopamine agonists pergolide and bromocriptine in the treatment of Parkinson’s disease. European Journal of Neurology. 1997; 4(6): 537–543.

Quinn Niall. Fortnightly review: Drug treatment of Parkinson’s disease. BMJ. 1995; 310: 575–579.

Hely Mariese A et al. The Sydney Multi-centre study of Parkinson’s disease: a randomised, prospective five-year study comparing low dose bromocriptine with low dose levodopa-carbidopa. Journal of Neurology, Neurosurgery & Psychiatry. 1994; 57(8): 903–910.

Pezzoli G, et al. Pergolide mesylate in Parkinson’s disease treatment. Journal of Neural Transmission. Supplementum. 1995; 45: 203–212.

Schwarz Johannes, Klaus Scheidtmann, Claudia Trenkwalder. Improvement of motor fluctuations in patients with Parkinson’s disease following treatment with high doses of pergolide and cessation of levodopa. European Neurology. 1997; 37(4): 236–238.

Schwab RS. Apomorphine in Parkinson’s disease. Trans Am Neurol Assoc. 1951; 56: 251–253.

Cotzias George C, et al. Similarities between neurologic effects of L-dopa and of apomorphine. New England Journal of Medicine. 1970; 282(1): 31–33.

Ostergaard L, et al. Pen injected apomorphine against off phenomena in late Parkinson’s disease: a double blind, placebo-controlled study. Journal of Neurology, Neurosurgery & Psychiatry. 1995; 58(6): 681–687.

Stibe CMH, et al. Subcutaneous apomorphine in parkinsonian on-off oscillations. The Lancet. 1988; 1(8582): 403–406.

Frankel JP, et al. Subcutaneous apomorphine in the treatment of Parkinson’s disease. Journal of Neurology, Neurosurgery & Psychiatry. 1990; 53(2): 96–101.

Kapoor R, et al. Intranasal apomorphine: a new treatment in Parkinson’s disease. Journal of Neurology, Neurosurgery, and Psychiatry. 1990; 53(11): 1015.

Hughes Andrew J et al. Rectal apomorphine in Parkinson’s disease. Lancet (British edition). 1991; 337(8783): 118.

Lees AJ et al. Sublingual apomorphine and Parkinson's disease. Journal of Neurology, Neurosurgery, and Psychiatry. 1989; 52(12): 1440.

Rinne UK et al. Cabergoline in the treatment of early Parkinson’s disease: results of the first year of treatment in a double-blind comparison of cabergoline and levodopa. Neurology. 1997; 48(2): 363–368.

Del Dotto P et al. Clinical and pharmacokinetic evaluation of L-dopa and cabergoline cotreatment in Parkinson’s disease. Clinical Neuropharmacology. 1997; 20(5): 455–465.

Korczyn Amos D, et al. Ropinirole versus bromocriptine in the treatment of early Parkinson’s disease: a 6‐month interim report of a 3‐year study. Movement Disorders: Official Journal of the Movement Disorder Society. 1998; 13(1): 46–51.

Lieberman Abraham et al. A multicenter trial of ropinirole as adjunct treatment for Parkinson’s disease. Neurology. 1998; 51(4): 1057–1062.

Rascol O, et al. Ropinirole in the treatment of levodopa-induced motor fluctuations in patients with Parkinson’s disease. Clinical Neuropharmacology. 1996; 19(3): 234–245.

Schwab Robert S et al. Amantadine in the treatment of Parkinson’s disease. JAMA. 1969; 208(7): 1168–1170.

Bailey EV, TW Stone. The mechanism of action of amantadine in Parkinsonism: a review. Archives Internationales de Pharmacodynamie et de Therapie. 1975; 216(2): 246–262.

Kulisevsky Jaime, Eduardo Tolosa. Therapy of Parkinson’s Disease. Amantadine in Parkinson’s Disease. 3rd edition. New York: Marcel Dekker; 1990. pp. 143–160.

Kornhuber J, M Streifler. Neuro-Psychopharmaka Adamantanamine. Vienna: Springer; 1992. pp. 59–76.

Kornhuber Johannes et al. Effects of the 1-amino-adamantanes at the MK-801-binding site of the NMDA-receptor-gated ion channel: a human postmortem brain study. European Journal of Pharmacology: Molecular Pharmacology. 1991; 206(4): 297–300.

Metman L Verhagen, et al. Amantadine as treatment for dyskinesias and motor fluctuations in Parkinson’s disease. Neurology. 1998; 50(5): 1323–1326.

Kaakkola Seppo, Ariel Gordin, Pekka T Männistö. General properties and clinical possibilities of new selective inhibitors of catechol O-methyltransferase. General Pharmacology: The Vascular System. 1994; 25(5): 813–824.

Keränen T et al. The effect of catechol-O-methyl transferase inhibition by entacapone on the pharmacokinetics and metabolism of levodopa in healthy volunteers. Clinical Neuropharmacology. 1993; 16(2): 145–156.

Duvoisin Roger C. Cholinergic-anticholinergic antagonism in parkinsonism. Archives of Neurology. 1967; 17(2): 124–136.

Pondal Margarita, Teodoro Del Ser, Félix Bermejo. Anticholinergic therapy and dementia in patients with Parkinson’s disease. Journal of Neurology. 1996; 243(7): 543–546.

Kim Samuel D et al. Parkinson disease. Handbook of Clinical Neurology. 2018; 159: 173–193.


  • There are currently no refbacks.

Copyright (c) 2020 Research & Reviews: Journal of Neuroscience